While calling for a universal breast cancer risk assessment by the age of 25, the American College of Radiology (ACR) emphasized that ascertaining screening needs prior to the age of 40 is particularly important in high-risk populations such as Black women, who are 42 percent more likely to die from breast cancer in comparison to non-Hispanic White women.
Noting emerging literature support for supplemental imaging and earlier screening for women at high risk of breast cancer, the American College of Radiology (ACR) has updated its breast cancer screening guidelines.
Published online in the Journal of the American College of Radiology, the updated ACR breast cancer guidelines now recommend that annual digital mammography begin between the ages of 25 and 40 for women at high risk for breast cancer.
Emphasizing an ACR reclassification of Black women and other minority women as being at high risk for breast cancer, the authors of the updated recommendations noted continued disparities with respect to breast cancer mortality rates and advanced stage diagnosis.
In comparison to non-Hispanic White women, minority women are 58 percent more likely to have an advanced-stage breast cancer diagnosis and are 127 percent more likely to die from breast cancer before the age of 50, according to the authors of the guidelines. They noted that Black women, in particular, have double the risk of triple-negative breast tumors and have a 42 percent higher mortality risk for breast cancer in comparison to non-Hispanic White women.
“The latest scientific evidence continues to point to earlier assessment as well as augmented and earlier-than-age-40 screening of many women – particularly Black women and other minority women. These evidence-based updates should spur more informed doctor-patient conversations and help providers save more lives,” emphasized Debra Monticciolo, M.D., F.A.C.R., the lead author of the updated ACR breast cancer screening recommendations and division chief of breast imaging at the Massachusetts General Hospital in Boston, in an ACR press release.
(Editor’s note; For related content, see “Should Race and Ethnicity Factor into Starting Ages for Mammography Screening?,” “New Meta-Analysis Says MRI is Best Supplemental Imaging for Dense Breasts” and “Study Looks at Contributing Factors to Incomplete Follow-Up for BI-RADS 3 Findings.”)
Other updated recommendations included annual supplemental magnetic resonance imaging (MRI) for women with dense breasts at the age of 40 or earlier if they have other risk factors for breast cancer. In lieu of MRI, the ACR said women with dense breasts may consider alternative supplemental imaging such as contrast-enhanced mammography (CEM) or ultrasound.
Depending on the type of risk factors, the ACR also recommends initiation of annual mammography at the age of 30 and annual MRI surveillance between the ages of 25 to 30 for women with increased genetic risk of breast cancer and those with a lifetime breast cancer risk of greater than or equal to 20 percent.
For women who have been exposed to 10 Gy or greater cumulative chest radiation by the age of 30, the updated ACR breast cancer screening guidelines recommend the initiation of annual mammography screening at the age of 25 or eight years after radiation exposure. The ACR also recommends MRI surveillance in this population between the ages of 25 to 30.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.